April 22, 2026
When biotech companies seek funding—whether for a Series A, Series B, IPO, or strategic partnership—investors do not just look at clinical data. They also carefully review CMC information (Chemistry, Manufacturing, and Controls) to evaluate whether the product is manufacturable, scalable, and approvable. CMC readiness can heavily influence investment decisions. Here’s what you need to know […]
